Antipsychotic Agents
11
3
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
1 terminated out of 11 trials
85.7%
-0.8% vs benchmark
18%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
"Extended" (Alternate Day) Antipsychotic Dosing
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Relative Bioavailability of LY03010 Compared to Listed Drug
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Clozapine Induced Weight Gain
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
Pharmacoepigenetics of Bipolar Disorder Treatment
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)